Thermo Fisher Scientific (NYSE:TMO) Stock Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on April 7th. The trade occurred in the Representative’s “MERRILL LYNCH LONG TERM GROWTH” account.

Representative Julie Johnson also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/30/2025.
• Sold $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 4/22/2025.
• Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/22/2025.
• Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/15/2025.
• Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/11/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 4/11/2025.
• Sold $1,001 – $15,000 in shares of DT Midstream (NYSE:DTM) on 4/7/2025.
• Sold $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 4/7/2025.
• Sold $1,001 – $15,000 in shares of Howmet Aerospace (NYSE:HWM) on 4/7/2025.
• Sold $1,001 – $15,000 in shares of Carlisle Companies (NYSE:CSL) on 4/7/2025.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $412.15 on Friday. The company has a market capitalization of $155.58 billion, a P/E ratio of 24.93, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The business has a fifty day simple moving average of $453.88 and a two-hundred day simple moving average of $510.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.11 earnings per share. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were given a $0.43 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TMO shares. Barclays reduced their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Citigroup reduced their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada reduced their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Finally, UBS Group reduced their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $607.43.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at $59,506,950.58. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,075 shares of company stock valued at $7,305,942. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds and other institutional investors have recently modified their holdings of the company. Norges Bank bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $3,149,754,000. GAMMA Investing LLC lifted its stake in shares of Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock valued at $1,604,338,000 after acquiring an additional 1,433,444 shares during the last quarter. Nuveen LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at about $532,360,000. Finally, Kovitz Investment Group Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 1,905.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company’s stock valued at $469,889,000 after acquiring an additional 858,193 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.